VYXEOS is a fixed course of therapy that allows patients time off sAML treatment1,a,b
Administer first consolidation cycle 5 to 8 weeks after the start of the last induction1
The majority of patients received induction with VYXEOS in an inpatient setting during the Phase 3 trial2
51% of patients received consolidation with VYXEOS in an outpatient setting during the Phase 3 trial3
Learn the patient factors to consider for outpatient administration with VYXEOS
Second induction (if needed)1
Daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 liposome on Days 1 and 3
- In patients not achieving a response, start 2 to 5 weeks after first induction
Second consolidation (if needed)1
Daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 liposome on Days 1 and 3
- 5 to 8 weeks after the start of first consolidation in patients who do not show disease progression or unacceptable toxicity
Dosing considerations
- Prior to initiating each cycle, calculate the prior cumulative anthracycline exposure for the patient1
- Assess cardiac function, complete blood counts, and liver and renal function before each consolidation cycle1
- Do not start consolidation until the absolute neutrophil count (ANC) recovers to greater than 0.5 Gi/L and the platelet count recovers to greater than 50 Gi/L in the absence of unacceptable toxicity1
- Patients may receive up to 2 cycles of induction and up to 2 cycles of consolidation.1
- All infusions administered intravenously.1